OOIR: Observatory of International Research

Papers

(The median citation count of HIV Medicine is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV	125
Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany	69
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021	62
Impact of coronavirus disease (COVID‐19) on HIV testing and care provision across four continents	61
Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy	48
The burden of non‐communicable diseases and mortality in people living with HIV (PLHIV) in the pre‐, early‐ and late‐HAART era	39
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023	38
Clinical epidemiology and outcome of HIV‐associated talaromycosis in Guangdong, China, during 2011–2017	36
Managing HIV‐associated inflammation and ageing in the era of modern ART	33
Chems4EU: chemsex use and its impacts across four European countries in HIV‐positive men who have sex with men attending HIV services	32
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium	27
Public understanding and awareness of and response to monkeypox virus outbreak: A cross‐sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency	27
BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022	26
Late diagnosis of HIV: An updated consensus definition	25
Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV	24
Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence	24
Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)	23
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials	23
Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohort	22
Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy	22
Comorbidities in women living with HIV: A systematic review	21
COVID‐19 in hospitalized HIV‐positive and HIV‐negative patients: A matched study	21
Interrogating the impact of combination antiretroviral therapies on HIV‐associated neurocognitive disorders	20
A review of reported cases of HIV pre‐exposure prophylaxis failure with resultant breakthrough HIV infections	19
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019	18

Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV‐1‐infected patients: a real‐world study in Japan	16
UK guideline for the use of HIV post‐exposure prophylaxis 2021	16
Alarming rates of virological failure and HIV‐1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY‐study in Cameroon	15
Prevalence of mental health conditions among people living with HIV during the COVID‐19 pandemic: A rapid systematic review and meta‐analysis	15
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age	15
The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV‐infected patients on suppressive antiretroviral therapy	15
A qualitative study of the impact of coronavirus disease (COVID‐19) on psychological and financial wellbeing and engagement in care among men who have sex with men living with HIV in Thailand	15
Acquired immune deficiency syndrome (AIDS) and late presentation in Poland – data from Test and Keep in Care (TAK) Polska project	15
Diagnostic value of serological biomarkers for detection of non‐alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV	15
Long‐acting injectable cabotegravir forPrEP: A game‐changer inHIVprevention?	15
Prevalence and incidence of pre‐diabetes and diabetes mellitus among people living with HIV in Ghana: Evidence from the EVERLAST Study	14
Comorbidities and co‐medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan	14
Caspofungin combined with TMP/SMZ as a first‐line therapy for moderate‐to‐severe PCP in patients with human immunodeficiency virus infection	14
Dyslipidaemia after switch to tenofovir alafenamide (TAF)‐based cART regimens in a cohort of HIV‐positive patients: what clinical relevance?	14
Incidence of recently acquired hepatitis C virus infection among HIV‐infected patients in southern Spain	14
Trends of age‐related non‐communicable diseases in people living with HIV and comparison with uninfected controls: A nationwide population‐based study in South Korea	13
Clinical outcomes of patients with and without HIV hospitalized with COVID‐19 in England during the early stages of the pandemic: a matched retrospective multi‐centre analysis (RECEDE‐C19 study)	13
Low awareness of and willingness to use PrEP in the Chinese YMSM: An alert in YMSM HIV prevention	13
Transmitted HIV‐1 drug resistance in a large international cohort using next‐generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study	12
Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV	12
Evaluation of an inner city HIV pre‐exposure prophylaxis service tailored to the needs of people who inject drugs	12
Characteristics and viral suppression among people living with HIV from the National Free Antiretroviral Therapy Programme, 2019	12
Mortality and AIDS‐defining events among young people following transition from paediatric to adult HIV care in the UK	12
Barriers and facilitators to HIV Pre‐Exposure Prophylaxis (PrEP) in Specialist Sexual Health Services in the United Kingdom: A systematic review using the PrEP Care Co	12
Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade	12
Virological failure and HIV drug resistance among adults living with HIV on second‐line antiretroviral therapy in the Asia‐Pacific	11
Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use	11
Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir‐ than with efavirenz‐based antiretroviral therapy	11
HIV DNA reservoir and elevated PD‐1 expression of CD4 T‐cell subsets particularly persist in the terminal ileum of HIV‐positive patients despite cART	11
British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020	11
COVID‐19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID‐19 pandemic in England	11
Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China	10
Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors	10
National strategies for vaccination against COVID‐19 in people living with HIV in Central and Eastern European region	10
Re‐assessing the late HIV diagnosis surveillance definition in the era of increased and frequent testing	10
Enabling CAR T‐cell therapies for HIV‐positive lymphoma patients – A call for action	10
Pre‐treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China	10
Prevalence of obesity and disturbances in glucose homeostasis in HIV‐infected subjects and general population – missed diagnoses of diabetes?	10
Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012	10
British HIV Association guidelines for the management of HIV‐2 2021	10
People with HIV have a higher risk of COVID‐19 diagnosis but similar outcomes to the general population	9
Late diagnosis of HIV in 2022: Why so little change?	9
Same‐day antiretroviral therapy initiation for people living with HIV who have tuberculosis symptoms: a systematic review	9
Long‐term success for people living with HIV: A framework to guide practice	9
Increased targeted HIV testing and reduced undiagnosed HIV infections among gay and bisexual men	9
Impact of COVID‐19 on HIV late diagnosis in a specialized German centre	9
FRAX assessment in people ageing with HIV	9
Outcomes of persistent low‐level viremia among HIV patients on antiretroviral therapy: A prospective cohort study	9
The success of HIV combination prevention: The Dean Street model	9
Increasing HIV early diagnosis by implementing an automated screening strategy in emergency departments	9

The association between use of chemsex drugs and HIV clinic attendance among gay and bisexual men living with HIV in London	9
Participation, retention and uptake in a multicentre pre‐exposure prophylaxis cohort using online, smartphone‐compatible data collection	8
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium	8
A retrospective cohort study of early mortality among patients with HIV/TB co‐infection in Shanghai municipality	8
Blood‐borne virus testing in emergency departments – a systematic review of seroprevalence, feasibility, acceptability and linkage to care	8
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium	8
Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance	8
Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps	8
Estimation of the determinants for HIV late presentation using the traditional definition and molecular clock‐inferred dates: Evidence that older age, heterosexual risk group and more recen	8
Where are we with pre‐exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group	8
The impact of COVID‐19‐related restrictions in 2020 on sexual healthcare use, pre‐exposure prophylaxis use, and sexually transmitted infection incidence among men who have sex with men in A	8
Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial	8
Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score	8
Abstracts	8
Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study	7
Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS)	7
Three‐year efficacy of switching to dolutegravir plus lamivudine: A real‐world study	7
Immune restoration affects 10‐year survival in people living with HIV/AIDS	7
Factors associated with human immunodeficiency virus‐1 low‐level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China	7
Failure to eradicate Helicobacter pylori infection is more frequent among HIV‐positive patients	7
Bioactive phytocompound mulberroside C and endophytes of Morus alba as potential inhibitors of HIV‐1 replication: a mechanistic evaluation	7
Cognitive ageing is premature among a community sample of optimally treated people living with HIV	7
Association of low‐level viremia with mortality among people living with HIV on antiretroviral therapy in Dehong, Southwest China: A retrospective cohort study	7
The role of CD8 T cells in controlling HIV beyond the antigen‐specific face	7
Ageing with HIV in the United States: Changing trends in inpatient hospital stays and comorbidities, 2003–2015	7
Pneumocystis jirovecii pneumonia PCR test on upper respiratory tract swab	7
Adverse perinatal outcomes associated with timing of initiation of antiretroviral therapy: Systematic review and meta‐analysis	7
Trends in antiretroviral use in pregnancy in the UK and Ireland, 2008–2018	7
Virological response and resistance profile in highly treatment‐experienced HIV‐1‐infected patients switching to dolutegravir plus boosted darunavir in clinical practice	7
Delayed HIV diagnosis during the COVID‐19 pandemic in Poland: A call for targeted HIV testing for those under suspicion of SARS‐CoV‐2	7
The recent natural history of human papillomavirus cervical infection in women living with HIV: A scoping review of meta‐analyses and systematic reviews and the construction of a hypothetic	7
Relationship of polypharmacy to HIV RNA suppression in people aged ≥ 50 years living with HIV	7
Endothelial activation is associated with intestinal epithelial injury, systemic inflammation and treatment regimen in children living with vertically acquired HIV‐1 infection	7
Factors partitioning physical frailty in people aging with HIV: A classification and regression tree approach	7
Chemsex and antiretroviral prescribing in an HIV cohort in Brighton, UK	7
Longitudinal analysis of new‐onset non‐AIDS‐defining diseases among people living with HIV: A real‐world observational study	7
Associations of marijuana with markers of chronic lung disease in people living with HIV	6
Immune response to mRNA‐based COVID‐19 booster vaccination in people living with HIV	6
HIV‐associated neurocognitive impairment in stable people living with HIV on ART in rural Tanzania	6
Weight changes, metabolic syndrome and all‐cause mortality among Asian adults living with HIV	6
HIV prevalence and HIV clinical outcomes of transgender and gender‐diverse people in England	6
Advanced HIV disease: A review of diagnostic and prophylactic strategies	6
Abstracts	6
Healthcare delivery for HIV‐positive people with tuberculosis in Europe	6
High residual inflammation despite HIV viral suppression: Lessons learned from real‐time adherence monitoring among people with HIV in Africa	6
HIV/AIDS post‐exposure prophylaxis knowledge and uptake among health professionals in Africa: Systematic review and meta‐analysis	6
Effectiveness of integrase strand transfer inhibitors in HIV‐infected treatment‐experienced individuals across Europe	6
Effect of an opt‐out point‐of‐care HIV‐1 nucleic acid testing intervention to detect acute and prevalent HIV infection in symptomatic adult outpatients and reduce HIV transmission in Kenya: a randomiz	6
Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross‐sectional and longitudinal analyses	6
Same‐dayand rapid initiation of antiretroviral therapy in people living withHIVin Asia. How far have we come?	6
Frailty and frailty screening: A qualitative study to elicit perspectives of people living with HIV and their healthcare professionals	6
GLP‐1 agonists for people living with HIV and obesity, is there a potential?	6
Modelling the impact of an HIV testing intervention on HIV transmission among men who have sex with men in China	6
Integrase strand transfer inhibitor treatment does not increase the incidence of immune reconstitution inflammatory syndrome in HIV‐infected Koreans	6
Potential drug–drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey	6
Menopausal status, age and management among women living with HIV in the UK	6
Predictors of in‐hospital mortality among HIV‐positive patients presenting with an acute illness to the emergency department	6
Objective and subjective rapid frailty screening tools in people with HIV	6
Use of antiretroviral therapy in pregnancy and association with birth outcome among women living with HIV in Denmark: A nationwide, population‐based cohort study	6
Transitioning from HIV post‐exposure prophylaxis to pre‐exposure prophylaxis in men who have sex with men	5
In utero and peripartum antiretroviral exposure as predictor of cognition in 6‐ to 10‐year‐old HIV‐exposed Ugandan children – a prospective cohort study	5
What problems associated with ageing are seen in a specialist service for older people living with HIV?	5
Viral hepatitis and the cascade of care among people living with HIV in the Asia‐Pacific	5
The National Evaluation of Malawi’s PMTCT Program (NEMAPP) study: 24‐month HIV‐exposed infant outcomes from a prospective cohort study	5
Is contact between men who have sex with men and non‐governmental organizations providing harm reduction associated with improved HIV outcomes?	5
Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co‐administration	5
Immune response to ART initiation in advanced HIV infection	5
Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: Nearly 40 years on	5
“Real world” efficacy of bulevirtide in HBV/HDV‐related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spa	5
Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV	5
HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe	5
Epidemiology, comorbidities at diagnosis and outcomes associated with HIV late diagnosis from 2010 to 2019 in a Belgian reference centre: A retrospective study	5
Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV	5
Why we need to re‐define long‐term success for people living with HIV	5
A matched cohort study investigating premature, accentuated, and accelerated aging in people living with HIV	5
The data‐collection on adverse effects of anti‐HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV	5
Non‐disclosure of HIV serostatus to sexual partners: Prevalence, risk factors and clinical impact in patients with HIV	5
Stopping and restarting PrEP and loss to follow‐up among PrEP‐taking men who have sex with men and transgender women at risk of HIV‐1 participating in a prospective cohort study in Kenya	5
The impact of COVID‐19 on HIV testing in the UK’s first Fast‐Track HIV city	5
Language matters: The importance of person‐first language and an introduction to the People First Charter	5

Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns	5
Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48‐week follow‐up study	5
No overall impact on rate of weight gain with integrase inhibitor‐containing regimens in antiretroviral‐naïve adults	5
Obesity in women living with HIV aged 45–60 in England: An analysis of the PRIME study	5
Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV‐positive individuals from the HIV‐HEART Study compared with the general population	5
Immune reconstitution inflammatory syndrome‐associated Graves disease in HIV‐infected patients: clinical characteristics and response to radioactive iodine therapy	5
Late diagnosis of HIV infection in Warsaw: Estimating the scale of the problem and demographic trends	5
The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV	5
“Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”	5
Economic impact on direct healthcare costs of missing opportunities for diagnosing HIV within healthcare settings	5
Tuberculosis incidence in country of origin is a key determinant of the risk of active tuberculosis in people living with HIV: Data from a 30‐year observational cohort study	4
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir‐based dual therapy. Bi‐lipid study	4
Follicle‐stimulating hormone in postmenopausal women living with HIV: a prevalence study	4
Perception of HIV physicians in Spain towards diagnosis and management of neuropsychiatric comorbidities in people with HIV	4
Gender differences in suicidal ideation, suicide attempts, and suicide death among people living with HIV: A systematic review and meta‐analysis	4
Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance	4
Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection	4
Associations between HIV, antiretroviral therapy and preterm birth in the US Women’s Interagency HIV Study, 1995–2018: a prospective cohort	4
Dolutegravir in real life: Self‐reported mental and physical health outcomes after transitioning from efavirenz‐ to dolutegravir‐based antiretroviral therapy in a prospective cohort study in Lesotho	4
Anticholinergic medications associated with falls and frailty in people with HIV	4
Associations between alcohol and cigarette use and type 1 and 2 myocardial infarction among people with HIV	4
CD4+ T‐cell recovery in HIV/hepatitis C co‐infected patients following successful hepatitis C treatment	4
High‐level compliance to opt‐out HIV testing in the emergency department (ED) of a large teaching hospital using the biochemistry sample as the sample type for HIV scr	4
Effect of HIV and antiretroviral therapy use on body weight changes in a cohort of U.S. veterans living with and without HIV	4
Prescribing patterns of antiretroviral treatments during pregnancy for women living with HIV in Canada 2004–2020: A surveillance study	4
Estimating the risk of mortality attributable to recent late HIV diagnosis following admission to the intensive care unit: A single‐centre observational cohort study	4
Gender‐affirming hormone therapy decreases d‐dimer but worsens insulin sensitivity in transgender women	4
British HIV Association guidelines on the management of opportunistic infection in people living with HIV: the clinical management of gastrointestinal opportunistic infections 2020	4
Multidisciplinary collaborative integrated management of increasingly prominent HIV complications in the post‐cART era	4
Predictors of low‐level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort	4
The role of an artificial intelligence model in antiretroviral therapy counselling and advice for people living with HIV	4
The role of HIV as a risk modifier for coronary endothelial function in young adults	4
Who’s slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first‐line HIV treatment in Uganda and South Africa	4
Coverage of maternal viral load monitoring during pregnancy in South Africa: Results from the 2019 national Antenatal HIV Sentinel Survey	4
The propositive study: Immunogenicity and safety of a four‐component recombinant protein‐based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living	4
Urinary biomarkers of early renal injury in antiretroviral‐naïve HIV‐positive persons in Shanghai, China: comparison with the general population	3
Long‐term outcomes for children and adolescents with Kaposi sarcoma	3
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV‐positive people without viral hepatitis in the Swiss HIV Cohor	3
The value of herpes zoster prevention in people aging with HIV: A narrative review	3
Efficacy of an electronic reminder for HIV screening in primary healthcare based on indicator conditions in Catalonia (Spain)	3
Loss to follow‐up among human immunodeficiency virus‐positive postpartum women and its predictive factors: A retrospective study	3
Neurocognitive evaluation using the International HIV Dementia Scale (IHDS) and Montreal Cognitive Assessment Test (MoCA) in an HIV‐2 population	3
Short report: Characterizing HIV care among a clinical sample of transgender women living with HIV	3
Impact of social determinants of health on time to antiretroviral therapy initiation and HIV viral undetectability for migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite	3
Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infection	3
Cerebrospinal fluid virology in people with HIV	3
Validation of the D:A:D chronic kidney disease risk score in people living with HIV: the IeDEA West Africa Cohort Collaboration	3
Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV‐specific risk factors; the Archi‐Prevaleat project	3
Long‐term clinical, virological and immunological outcomes following planned treatment interruption in HIV‐infected children	3
Development and internal validation of the HIV In‐hospital Mortality Prediction (HIV‐IMP) risk score	3
Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV‐infected people from the French Dat'AIDS cohort: A propensity score	3
Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abaca	3
Barriers to early diagnosis and treatment of severely immunosuppressed patients with HIV‐1 infection: A quantitative and qualitative study	3
No overall impact on body mass index for age change after dolutegravir initiation in a French paediatric cohort	3
Treatment‐emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series	3
Low‐level HIV viraemia during antiretroviral therapy: Longitudinal patterns and predictors of viral suppression	3
Markers of ovarian reserve in women living with HIV: A systematic review	3
Obesity and diabetes in people of African ancestry with HIV	3
Frailty and sarcopenia among Turkish people aged 40 and above living with HIV	3
Poster Abstracts	3
A call for health systems to monitor the health‐related quality of life of people living with HIV	3
Standardizing HIV post‐exposure prophylaxis in the emergency department following sexual assault	3
Incidence of and risk factors for liver damage in patients with HIV‐1 mono‐infection receiving antiretroviral therapy	3
Predictors of knowledge of and access to biomedical prevention among MSM and transgender men in Latin America: Results from the Latin American internet survey	3
HIV self‐test: a tool to expand test uptake among men who have sex with men who have never been tested for HIV in São Paulo, Brazil	3
Poster Abstracts	3
Failure to return pillbox is a predictor of being lost to follow‐up among people living with HIV on antiretroviral therapy in rural Tanzania	3
Antiretroviral drug switches to zidovudine‐based regimens and loss to follow‐up during the first COVID‐19 lockdown in Bali, Indonesia	3
Mapping frailty in people living with HIV: A nationwide study in Greece	3
Utilization of absolute monocyte counts to predict cardiovascular events in people living with HIV	3
Pilot evaluation of PrEP EmERGE – A novel digital health innovation designed to support sexual health clinics and HIV‐PrEP users	3
Archiving of mutations in HIV‐1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP‐READY study	3
High mortality among patients hospitalized for drug‐resistant tuberculosis with acquired second‐line drug resistance and high HIV prevalence	3
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation	3
Evaluating virological outcomes in people with HIV on stable antiretroviral therapy with reduced frequency of HIV viral load monitoring during the COVID‐19 pandemic	3
Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III	3
Associations between HIV infection and frailty status and its individual components: Are frailty components disproportionally affected?	3
Assessing risk factors for hypertension in young adults with perinatally acquired HIV infection: A case–control study	3
Statin gap in patients living with HIV: assessing dose appropriateness	3
COVID‐19 hospitalization outcomes in adults by HIV status; a nation‐wide register‐based study	3
The incidence of and risk factors for hospitalized acute kidney injury among people living with HIV on antiretroviral treatment	3
Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process	3
Network meta‐analysis of post‐exposure prophylaxis randomized clinical trials	3
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study	3
Risk of severe clinical events after sustained virological response following direct‐acting antiviral therapy in HIV and hepatitis C virus coinfected participants	3
Positive Outcomes: Validity, reliability and responsiveness of a novel person‐centred outcome measure for people with HIV	3
Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS)	3
Metabolic‐Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort	3
Differences in hypertension and prehypertension among people living with and without HIV in China: role of HIV infection and antiretroviral therapy	3
Early HIV treatment and survival over six years of observation in the ANRS 12249 Treatment as Prevention Trial	3
Who is lost to follow‐up in HIV care? Assessment of care retention over time and the impact of COVID‐19. Longitudinal analysis of the PISCIS cohort	3
HIV and fracture: Risk, assessment and intervention	3
IgG seroprevalence of COVID‐19 among people living with HIV or at high risk of HIV in south‐west Germany: A seroprevalence study	3
SARS‐CoV‐2 vaccine immunogenicity for people living with HIV: A systematic review and meta‐analysis	2
Disparities in healthcare access and utilization among people living with HIV in China: A scoping review and meta‐analysis	2